Shots: The approval is based on the results of P-III DRIVE-AHEAD and DRIVE-FORWARD trial assessing Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) & Pifeltro vs darunavir + ritonavir (DRV+r) + FTC/TDF or abacavir (ABC)/3TC respectively for a duration of 48/96 wks. DRIVE-AHEAD and DRIVE-FORWARD results: suppression of HIV-1 RNA @ 48 wks. (84%, 83% […]Read More
Shots: • CHMP approval is based on two P-III trials i.e. DRIVE-AHEAD and DRIVE-FORWARD assessing (Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/TDF) and (Pifeltro vs darunavir +ritonavir +FTC/TDF/abacavir (ABC)/3TC)) for 48 wks., showing its safety and efficacy • On 30 Aug, 2018 the US FDA approved Delstrigo and Pifeltro for the treatment of HIV-1 infection in adult […]Read More
Shots: The approval is based on P-III DRIVE-FORWARD study assessing Pifeltro (qd) vs darunavir + ritonavir (DRV+r) (800mg, 100 mg, qd) each in combination with emtricitabine (FTC)/TDF or abacavir (ABC)/3TC in patients with HIV-1 infection P-III DRIVE-FORWARD study results: @48 wks. viral suppression of HIV-1 RNA <40 copies/mL (83% vs 79%); @96 wks. (72% vs […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
